Jpmorgan Chase & CO Indaptus Therapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Indaptus Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 19 shares of INDP stock, worth $18. This represents 0.0% of its overall portfolio holdings.
Number of Shares
19
Previous 15
26.67%
Holding current value
$18
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding INDP
# of Institutions
18Shares Held
605KCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA256KShares$251,1390.0% of portfolio
-
Investment House LLC Las Vegas, NV100KShares$97,9760.01% of portfolio
-
Geode Capital Management, LLC Boston, MA73.1KShares$71,6660.0% of portfolio
-
Strategy Asset Managers LLC45.3KShares$44,4290.01% of portfolio
-
Pine Valley Investments LTD Liability CO Marlton, NJ44KShares$43,1030.0% of portfolio
About Indaptus Therapeutics, Inc.
- Ticker INDP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 8,258,600
- Market Cap $8.09M
- Description
- Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B v...